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NANOPARTICLES BASED ON FRUCTOSE AND ALKALY_EARTH HALOGENIDES
WITH SECOND HARMONIC GENERATION PROPERTIES FOR APPLICATIONS AS
BIO-SENSORS AND FOR RADIOTHERAPY
In recent years, some Metal Organic Frameworks (MOFs) with Second Harmonic Generation (SHG) properties, based on fructose and alkali-earth
alogenides, were investigated to understand the effect of cation size and anion polarizability on crucial quantities correlated to the non-linear
optical (NLO) response, such as hyperpolarizability and optical susceptibility [1,2]. The compounds studied are interesting for biomedicine
applications, as they combine high biocompatibility, due to their non-toxic components, and significant SH emission, that can permit exploitation
for in vitro bio-imaging.
Results from our previous work [2] (figure 1) suggested that the SH efficiency is much influenced by the anion, the first static hyperpolarizability
and second order susceptibility being higher for bromide compounds with respect to those with chloride.
In order to enhance the SH efficiency of our systems, we decided to synthetized three new MOFs with iodide as anion, instead of bromide and
chloride. In particular we obtained three MOFs based on fructose and SrI2 salts, of formula [Sr(fructose)2]I2, [Sr2(fructose)3]I4H2O and
[Sr(fructose)(H2O)3I]I (figure 2), that contain quite the same building blocks but show different structural arrangements. The compounds were
characterized by single-crystal and powder XRD, and the first static hyperpolarizability and second-order susceptibility were estimated from
theoretical calculations, both in vacuo and in the solid state (table 1) [3], and measured with the Kurtz and Perry method.
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Table 1. Crystal data and preliminary theoretical results on the fructose-SrI2
based MOFs.
Figure 1: Isomorphous structure of the four compounds of formula
[M(fructose)2(H2O)2]X2H2O, M=Ca,Sr and X=Cl, Br [2].
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Radiotherapy applications.
Applications in radiotherapy of MOFs based on the co-crystallization of fructose and salts containing
various radionuclides are presently under investigation. For example, 89Sr, is a - emitter with a half-life of
50.57 d obtained by nuclear fission and used in the form of chloride for metastasized bone cancer.
The average energy of the - emitted by 89Sr is 0.58 MeV. Based on a linear energy transfer in water of
1.75 MeV cm-1, we calculate an average range of 3.3 mm and we assume a tumor size at least one order of
magnitude larger. Under this hypothesis, the estimated dose delivered by functionalized particles of
[Sr(fructose)2(H2O)2]Cl2H2O of radius 0.5 m prepared with commercial strontium chloride with specific
activity 4.57 MBq/mg would be 23.7 Gy. However, the selectivity towards tumor cells would be greatly
enhanced with respect to strontium chloride itself.
Synthesys of nanoparticles.
Nanoparticles of [Sr(fructose)2(H2O)2]Cl2H2O were obtained by fast precipitation of crystals from isobutanol solution, dryed in a
stove at 70°C and grinded in a bill mill. Then the nanoparticles were proofed through reaction of the –OH groups on surface with
dodecanoyl chloride and encapsulated in a phospholipidic m-PEG shell. They were characterized by Dynamic light scattering
technique (DLS), showing a narrow band centered at ca. 245 nm (polidispersity 0.005).
[Sr(fructose)2]I2 [Sr2(fructose)3]I4H2O [Sr(fructose)(H2O)3I]I
Lattice Monoclinic Ortorhombic Ortorhombic
Space group P21 P212121 P212121
Cell dimensions 7.8592 
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90 
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Cell volume 1010.37 3809.46 1617.63
Density calc (g cm-3) 2.307 2.225 2.364
 (mm-1) 28.24 29.80 7.179
Asymmetric unit
content
Sr2+
2 FRU
2 I-
2 Sr2+
3 FRU
3 H2O
4I-
1 H2Ocrist
Sr2+
FRU
3 H2O
2 I-
tot
(1)  (10-30 cm5 esu-1) 27.0 18.0 14.7
(2) pmV-1 5.6 3.2 ND
I/Isucr (measured)
(2) 0.7 0.05
(1) Calculated at the B3LYP/631G(d) level of theory with Gaussian09.
(2) Measured values obtained from powders, with the Kurtz and Perry method.
Cell uptake and viability tests.
Preliminary activity studies on target cells are in progress.
Nanoparticles were tested on two cell lines, hTERT-HME1 (breast
epithelial cells immortalized with hTERT) and HT-29 (colorectal
adenocarcinoma) to evaluate cellular uptake and viability.
To study cellular uptake, nanoparticles were loaded with
fluorescein (1 mg/20 mg of the compound) before treatment
with dodecanoyl chloride and their internalization was expressed
as median fluorescence intensity. Preliminary data suggested that
cellular uptake was dose- and time-dependent.
Cell viability was evaluated after 1, 2 and 5 days of treatment and
was measured as ATP production.
Nanoparticles inhibited the growth of cells by about 50% at the
maximum concentration after 5 days of treatment.
[Sr(fructose)(H2O)3I]I
Figure 2. Structure arrangements of the three fructose-SrI2 based MOFs.
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[Sr(fructose)(H2O)3I]I
COMPONENT BETA CHI(2) d(MKS) d(cgs)
XYZ -178.0043 -0.1025 -0.0996 -0.002
[Sr(fructose)2]I2
COMPONENT BETA CHI(2) d(MKS) d(cgs)
XXY 569.3482 0.5247 0.5102 0.0122
XYZ -422.3184 -0.3892 -0.3784 -0.009
YYY -760.5659 -0.7009 -0.6815 -0.016
YZZ -167.1856 -0.1541 -0.1498 -0.004
[Sr2(fructose)3]I4H2O
COMPONENT BETA CHI(2) d(MKS) d(cgs)
XYZ 280.4013 0.0685 0.0666 0.0016
Theoretical calculation has been obtained at the PBE0 level with 3-21G split valence basis set. [4]
Exploiting symmetry in solid-state simulations
= +
COMPONENT BETA CHI(2) d(MKS) d(cgs)
XXY -0.4875 -0.0004 -0.0004 0
XYZ 0.5208 0.0005 0.0005 0
YYY 4.6095 0.0042 0.0041 0.0001
YZZ -0.1603 -0.0001 -0.0001 0
COMPONENT BETA CHI(2) d(MKS) d(cgs)
XXY 140.061 0.1291 0.1255 0.003
XYZ -16.3986 -0.0151 -0.0147 -0.0004
YYY 370.3652 0.3413 0.3319 0.0079
YZZ -321.518 -0.2963 -0.2881 -0.0069
Substructure decomposition of Srfrui1
• beta terms are not pairwise additive
• if estimated tensor components are high
for a given specie, it is reasonable to
assume that the contribution to BETA of
that specie will be relevant as well in the
whole structure
• Results the sugar provides the largest
contribution
@Marconi ‘Knights Landing’
partition, 1 x 68-cores Intel Xeon Phi
7250 CPU @1.4 GHz – Simulations
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Applications
[Sr(fructose)2]I2 [Sr2(fructose)3]I4H2O
Periodic LCGTF calculations (CRYSTAL14)
Table 2. Mean diameter (nm) and multimodal size distribution
of nanoparticles determined by DLS.
Next step provide for the functionalization of the nanoparticles surfice in
order to direct them towards specific cancer cells.
